CHARGE syndrome is an autosomal dominant disorder caused in about two-third of cases by mutations in the CHD7 gene. For other genetic diseases e.g. hereditary spastic paraplegia, it was shown that interacting partners are involved in the underlying cause of the disease. These data encouraged us to search for CHD7 binding partners by a yeast two-hybrid library screen and CHD8 was identified as an interacting partner. The result was confirmed by a direct yeast two-hybrid analysis, co-immunoprecipitation studies and by a bimolecular fluorescence complementation assay. To investigate the function of CHD7 missense mutations in the CHD7 -CHD8 interacting area on the binding capacity of both proteins, we included three known missense mutations (p.His2096Arg, p.Val2102Ile and p.Gly2108Arg) and one newly identified missense mutation (p.Trp2091Arg) in the CHD7 gene and performed both direct yeast two-hybrid and co-immunoprecipitation studies. In the direct yeast two-hybrid system, the CHD7 -CHD8 interaction was disrupted by the missense mutations p.Trp2091Arg, p.His2096Arg and p.Gly2108Arg, whereas in the co-immunoprecipitation studies disruption of the CHD7 -CHD8 interaction by the mutations could not be observed. The results lead to the hypothesis that CHD7 and CHD8 proteins are interacting directly and indirectly via additional linker proteins. Disruption of the direct CHD7 -CHD8 interaction might change the conformation of a putative large CHD7 -CHD8 complex and could be a disease mechanism in CHARGE syndrome.
INTRODUCTION
CHARGE syndrome (OMIM 214800) is an autosomal dominant malformation syndrome. The disorder is characterized by variable combinations of coloboma, heart defects, atresia of the choanae, retarded growth and development, genital hypoplasia, ear anomalies and deafness (1 -3) . Additional features such as cranial nerve palsy, semicircular canal agenesis, cleft lip/palate, tracheo-oesophageal fistula and renal anomalies are described (4 -6) .
Mutations in the CHD7 gene are the major cause of CHARGE syndrome (4, 5, (7) (8) (9) (10) . A large cohort of patients, who had received the clinical diagnosis CHARGE syndrome, was tested for CHD7 mutations and the clinical spectrum was studied. Prominent differences in the phenotype could not be observed between the mutation-positive and the mutationnegative groups (4) . CHD7 belongs to the CHD (chromodomain helicase DNA binding) family of proteins, which share the combination of two N-terminal chromodomains, followed by a * To whom correspondence should be addressed at: Institute of Human Genetics, Heinrich-Düker-Weg 12, D-37073 Göttingen, Germany. Tel: +49 551399016; Fax: +49 551397567; Email: spauli@gwdg.de SWI2/SNF2-like ATPase/helicase domain (11) (12) (13) . The CHD group can be further divided into three subgroups according to sequence similarities and additional functional domains. CHD7 belongs together with CHD6, CHD8 and CHD9 to subgroup III. Distinctive features of this subgroup are the presence of three conserved regions (CR1-CR3), a SANT domain and two BRK domains (14, 15) . To date, the molecular functions of subgroup III members are poorly understood.
CHD family members are involved in chromatin remodelling as it was shown for CHD1 (14, 16) . Alterations in chromatin structure are important for the regulation of gene transcription, DNA repair, replication and recombination. Chromatin remodelling enzymes can be divided into two categories, those that alter chromatin structure by histone modification (17) and those that alter the histone-DNA contacts within the nucleosome by using energy of ATP hydrolysis (18) . Members of the CHD group belong to the SNF2 superfamily of ATPdependent chromatin remodelers (12, 15) . For most SNF2-like ATPases, it was shown that they are components of large multisubunit complexes. For some CHD family members, several protein-protein interactions have been described. Chd1 of S. cerevisiae is a component of the two highly homologous acetyltransferase complexes SAGA and SLIK (19) , CHD3 acts together with CHD4 as components of the nucleosomeremodelling and histone deacetylase (NuRD) complex (14) . CHD8 interacts directly with WDR5 (20) , a component of the histone H3 Lys-4 methyltransferase MLL complex (21) .
CHD7 interacts in vitro with its chromodomains with methylated forms of H3K4 (22) . It was shown that during mouse ES cell differentiation, the CHD7 sites change with the H3K4 pattern and the CHD7 sites are predominantly located distal to transcription start sites (22) . Because of these observations, it was suggested that CHD7 plays a role in enhancer mediated transcription of key target genes (22) .
On the basis of sequence similarities between CHD7 and other CHD members, it can be suggested that CHD7 acts in a large multisubunit complex. Therefore, binding partners of CHD7 could be candidate genes for CHARGE syndrome.
For other diseases, e.g. hereditary spastic paraplegia (HSP), it was shown that interacting partners are involved in the underlying cause of the disease. Mutations in spastin (SPG4) and in its binding partner ZFYVE27 (SPG33) lead to HSP (23) . In Cornelia de Lange syndrome, mutations in the cohesion regulators NIPBL and ESCO2 and in different components of the cohesion complex (SMC1A and SMC3) were reported (24) . These data from the literature encouraged us to search for CHD7 binding partners by a yeast two-hybrid library screen using a part of CHD7 as bait. In our yeast twohybrid library screen, we identified CHD8, another CHD subgroup III member, as a specific interaction partner of CHD7. We confirmed this result by direct yeast two-hybrid studies, co-immunoprecipitation experiments and by a bimolecular fluorescence complementation assay (BiFC-Assay). Furthermore, we characterized the interacting part of CHD7 and CHD8, introduced four missense mutations in the CHD7 interacting part and performed direct yeast two-hybrid experiments and co-immunoprecipitation studies. In the yeast two-hybrid system, the CHD7 -CHD8 interaction was disrupted by three missense mutations (p.Trp2091Arg, p.His2096Arg and p.Gly2108Arg), whereas in the co-immunoprecipitation studies no disruption of the CHD7 -CHD8 interaction by the mutations could be observed. These findings indicate that CHD7 and CHD8 are interacting directly and indirectly via additional linker proteins. Loss of the direct CHD7 -CHD8 interaction might change the conformation of a possible CHD7 -CHD8 containing complex, which might be a disease mechanism in CHARGE syndrome.
RESULTS

Identification of CHD8 as a potential binding partner of CHD7 by Y2H library screening
To identify CHD7 interacting proteins, we screened a human foetal brain cDNA library (BD Clontech). The plasmid CHD7-CR1-3-pGBKT7 (amino acids 1591 -2181) containing the three conserved regions CR1 -CR3 and the SANT domain of the CHD7 protein was used as bait. We screened 3.34 × 10 7 clones and identified 21 clones, which were able to grow in selective media. Eighteen clones were also positive for a-galactosidase expression. From these clones, plasmids were isolated and sequenced. Eleven clones contained parts of the coding region of CHD8. One clone showed a correct reading frame, whereas in 10 clones the reading frame of the CHD8 region to the GAL4 activation domain was incorrect. The correct clone encodes the protein region from amino acids 1789-2091 (NP_065971.2) of the CHD8 protein and this clone was used in further experiments.
Confirmation of the CHD7 -CHD8 interaction by direct Y2H experiments
To specify the CHD7 -CHD8 interacting area, we performed direct Y2H experiments using the plasmids CHD7-CR1-pGBKT7 (amino acids 1593-1768), CHD7-CR2-pGBKT7 (amino acids 1701 -1948) and CHD7-CR3-pGBKT7 (amino acids 1950 -2172) as bait, respectively. These plasmids contain either the conserved region 1, or 2 or 3 (Figs 1 and  2A ). CHD7 -CHD8 interaction could only be observed in the part-spanning amino acids 1950 -2172, containing the conserved region 3 (CR3) of the CHD7 protein ( Fig. 2A) . The three known missense mutations p.His2096Arg, p.Val2102Ile and p.Gly2108Arg (4, 25, 26) identified in CHARGE patients are located within this CHD7 -CHD8 interacting area. Furthermore, we identified in a patient with atypical CHARGE syndrome another new missense mutation (p.Trp2091Arg) which resides also in this region. We created four new bait constructs for the interacting region (amino acids 1950 -2172), each containing one of these missense mutations (CHD7-His2096Arg-pGBKT7, CHD7-Val2102Ile-pGBKT7, CHD7-Gly2108Arg-pGBKT7 and CHD7-Trp2091Arg-pGBKT7, Fig. 1 ) and performed direct yeast two-hybrid experiments with the CHD8-pGADT7-Rec plasmid as prey. The CHD7 -CHD8 interaction was disrupted by the missense mutations p.Trp2091Arg, p.His2096Arg and p.Gly2108Arg, but not by the missense mutation p.Val2102Ile.
To narrow down the interacting area of CHD8, we created two new prey constructs, CHD8-pGADT7-1 (amino acids 1789-1983) and CHD8-pGADT7-2 (amino acids 1985-2091). The CHD8-pGADT7-2 includes the first BRK domain, while Human Molecular Genetics, 2010, Vol. 19, No. 14 2859
CHD8-pGADT7-1 does not code for a known protein domain. We performed again a direct yeast two hybrid with all four CHD7 plasmids containing missense mutations and with the plasmid CHD7-CR3-pGBKT7 as positive control and the plasmid CHD7-CR1-pGBKT7 as negative control. We identified the CHD7-CHD8 interaction within the CHD8 part spanning the amino acids 1789-1983. This result supports our observation that the missense mutations p.Trp2091Arg, p.His2096Arg and p.Gly2108Arg disrupt the interaction (Fig. 2B ).
CHD7 -CHD8 interaction analysed by bimolecular fluorescence complementation assay (BiFC-Assay)
To confirm the CHD7-CHD8 interaction, we performed a BiFC-Assay. The principle of this technique is based on the observation that splitted N-and C-terminal EGFP fragments do not emit a bright fluorescence. If the two splitted non-functional EGFP halves are fused to proteins that interact, they can functionally complement and emit a bright fluorescence (27) . HeLa cells were either transiently co-transfected with the plasmids CHD7-FPCA-V1 and CHD8-FPCA-V2 or transfected with a single plasmid as negative control. After 24 h, the cells were analysed for the presence of fluorescence complementation. As shown in Figure 3 , we observed in co-transfected cells a bright green fluorescence in the nucleus. Single-transfected cells did not show any fluorescence signal. Because fluorescence complementation was only observed in CHD7-CHD8 co-transfected cells, these results confirm the CHD7-CHD8 interaction shown in the yeast two-hybrid system.
CHD8 co-immunoprecipitates with CHD7
To further verify the CHD7-CHD8 interaction, we performed co-immunoprecipitation studies in HeLa cells. After transfection and cell culture for 24 h, the cells were lysed and protein extracts were prepared. A part of the CHD7 protein (amino acids 1593-2178) was fused to an HA-tag, while a part of the CHD8 protein (amino acids 1789 -2302) was fused to a c-Myc taq. The CHD7 part fused to the HA-tag was estimated to produce a 70 kDa protein fragment, while the CHD8 part labelled with a c-Myc tag was calculated to have a size of approximately 61 kDa. Using a c-Myc antibody for precipitation, we detected with an HA antibody a 70 kDa band corresponding to the estimated size of the CHD7 part (Fig. 4A ). The reciprocal experiment, precipitation with an HA antibody and detection with the c-Myc antibody lead to a specific band of about 68 kDa in size (Fig. 4B ). To further confirm the specificity of the observed bands, we precipitated with c-Myc and detected with the c-Myc antibody again the specific 68 kDa band, strongly supporting that this band corresponds to the CHD8-c-Myc fusion protein. The reciprocal experiment was also performed ( Fig. 4C and D) .
To investigate the influence of the missense mutations in the CHD7 gene in the CHD7 -CHD8 interacting area in an in vivo system, we performed co-immunoprecipitation studies with the CHD7-His2096Arg-pCMV-HA, CHD7-Val2102Ile-pCMV-HA, CHD7-Gly2108Arg-pCMV-HA and CHD7-Trp2091Arg-pCMV-HA plasmids, respectively. Interestingly, in all four cases, the mutated CHD7 part was co-immunoprecipitated with the CHD8 part ( Fig. 4E and F) .
DISCUSSION
Mutations in the CHD7 gene lead to CHARGE syndrome, which is a well-known congenital malformation syndrome. The CHD7 protein belongs to the CHD (chromodomain helicase DNA-binding domain) family of ATP-dependent chromatin remodelling enzymes. The human CHD family consists of Figure 1 . Schematic overview of the CHD7 protein and the constructs used as baits in the yeast two-hybrid assay. CHD7 consists of two N-terminal chromodomains, followed by a SWI2/SNF2-like ATPase/helicase domain, three conserved regions (CR1-CR3), a SANT domain and two BRK domains. The plasmids CHD7-CR1-pGBKT7, CHD7-CR2-pGBKT7 and CHD7-CR3-pGBKT7 divide the CHD7-CR1-3-pGBKT7 bait plasmids (black lane spanning amino acids 1591-2181) in three different parts. The bait plasmids (a) CHD7-Trp2091Arg-pGBKT7, (b) CHD7-His2096Arg-pGBKT7, (c) CHD7-Val2102Ile-pGBKT7 and (d) CHD7-Gly2108Arg-pGBKT7 were generated by introducing one of the missense mutations (Trp2091Arg, His2096Arg and Val2102Ile Gly2108Arg) into the CHD7-CR3-pGBKT7 part spanning the amino acids 1950-2172 of the CHD7 protein.
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Human Molecular Genetics, 2010, Vol. 19, No. 14 nine members, which can be grouped in three subgroups based on homologies in the sequence and domain architecture (12) . Chromatin remodelling is an important mechanism for the regulation of gene expression and it is known that chromatin remodelling is carried out by multi-protein complexes (28) . It can be hypothesized that CHD7 is also a component of a multisubunit complex. Identification and characterization of CHD7 binding proteins might provide insights into the molecular mechanism in which CHD7 is involved. In this study, we identified CHD8, another subgroup III member of the CHD family of proteins, as an interacting partner of CHD7 by a yeast two-hybrid library screen. The specificity of the interaction was confirmed by direct yeast two-hybrid studies, co-immunoprecipitation experiments and by a BiFC-Assay. CHD8 consists, such as CHD7, of two Nterminal chromodomains, followed by a SWI2/SNF2-like ATPase/helicase domain and specific for subgroup III members of three conserved regions (CR1 -CR3), a SANT domain and two BRK domains (12) . It has been shown that CHD8 interacts with human Staf (ZNF143), a zinc finger transcription factor, which controls the expression of the U6 gene (29) . Furthermore, CHD8 was co-purified with components of Human
the MLL1 -WDR5 complex (20, 30) and was found to interact directly with beta-catenin and playing a role in the regulation of beta-catenin target genes (20) . Mouse Chd8 was shown to bind via its BRK domains Ctcf, an insulator binding protein involved in insulation and epigenetic regulation (31) . With its tandem chromodomains, CHD8 binds in vitro specifically to histone H3 di-methylated at lysine 4 (32). CHD8 was also found to be associated with the elongating form of RNA polymerase II and to control the expression of cyclin E2 and thymidylate synthetase (32) . In Drosophila melanogaster, kismet is the only gene related to the subgroup III members of the CHD gene family. Kismet encodes for two isoforms, a large protein with a molecular weight of 574 kDa (KIS-L) and a small isoform of 225 kDa (KIS-S) (33, 34) . Kis-L is highly related to the human CHD7 or other CHD subgroup III members. Kis-L belongs to the trithorax group and was shown to play an important role in body segmentation and segment identity of Drosophila larvae (33) . Furthermore, it was suggested that kis-L is involved in an early step of transcriptional elongation by RNA Polymerase II (Pol II), because it is co-localized with most RNA-Polymerase II sites (32, 35, 36) . In kismet mutant larvae, a reduction in the levels of elongating Pol II and the elongation factors SPT6 and CHD1 was observed (35) . In contrast to Drosophila, CHD8 depletion in mammals does not reduce in general the levels of Ser2-phosphorylated RNA Polymerase II (32) . It was suggested that in mammals, the function of kismet is overtaken by several subgroup III members (CHD6 -CHD9) and that depletion of one subgroup III member leads to a gene-specific and not a general effect (32) . In the present study, we could show that two subgroup III members, namely CHD7 and CHD8, interact. We hypothesize that CHD7 and CHD8 together build a core component of a complex with similar functions such as kismet. Interestingly, the situation that two members of the same subgroup interact was found for the subgroup II members CHD3 and CHD4. In Drosophila, there is only a single gene related to subgroup II, named Mi-2. This Drosophila gene encodes also for two transcripts (15, 37) . In mammals, CHD3 and CHD4 were found to build together a core component of the NuRD complex (14, 38) .
Mutations in CHD7 interacting genes, which are involved in the same molecular mechanism, may also cause CHARGE syndrome. In three children with developmental delay, cognitive impairment and similar dysmorphic features a submicroscopic deletion on chromosome 14q11.2 was detected (39). (4, 25, 26) as well as a new identified missense mutation (p.Trp2091Arg) in the CHD7 gene recently found by our group in a CHARGE patient. We performed direct yeast twohybrid analyses and co-immunoprecipitation studies. In the direct yeast two-hybrid system, the CHD7 -CHD8 interaction was disrupted by the missense mutations, p.Trp2091Arg, p.His2096Arg and p.Gly2108Arg. The missense mutation p.Gly2108Arg was described in two different families with five affected members (26) . From the five affected members, only one fulfilled the diagnostic criteria for CHARGE syndrome while the others showed a very mild phenotype. Our patient with the missense mutation p.Trp2091Arg is also affected with atypical CHARGE syndrome. She has bilateral coloboma and microphthalmia of the left eye, microcephaly, mental retardation and unilateral deafness. In contrast to the results obtained in the direct yeast twohybrid experiments, co-immunoprecipitation studies did not reveal a disruption of the CHD7 -CHD8 interaction by the mutations described above. This discrepancy strongly indicates that CHD7 and CHD8 might be components of a larger complex. Direct yeast two-hybrid studies analyse the direct interaction of two proteins. A complex of proteins with different influences on binding partners, e.g. bridging proteins, cannot be studied by this method. However, co-immunoprecipitation studies can detect linker proteins between CHD7 and CHD8 which stabilizes a possible protein complex. For example, it was shown that mouse Chd8 binds Ctcf via its BRK domains (31) . For human CHD7, there was also an interaction with CTCF via its BRK domains observed (40) . We suggest that CHD7 and CHD8 are interacting directly (as we showed by our yeast two-hybrid results) and indirectly via additional linker proteins such as CTCF. Further studies are needed to discover such linker proteins, which could influence the severity of CHD7 mutations or which could be another underlying cause of CHARGE syndrome, if present in a mutated condition.
MATERIALS AND METHODS
Yeast two-hybrid analysis
Yeast two-hybrid screen. For the identification of putative CHD7 interacting partners, we used the MATCHMAKER TM human foetal brain cDNA library (BD, Clontech), which was pre-transformed into the yeast strain Y187. The bait plasmid CHD7-CR1-3-pGBKT7 was constructed by subcloning a fragment of CHD7 (amino acids 1591 -2181, containing the area of conserved regions 1 -3) into the pGBKT7 vector (Clontech) in frame to the GAL4 DNA-binding domain. The correct reading frame and the correct sequence were confirmed by sequencing the plasmid.
The bait plasmid CHD7-CR1-3-pGBKT7 was transformed into AH109 yeast strain cells and was tested for toxicity and autoactivation of the bait reporter genes. No toxicity for the yeast cells and no self-activation of the bait reporter genes could be observed. The AH109 yeast strain cells containing the bait plasmid were mated with the MATCHMAKER library Y187 cells. After mating, diploids were plated on leucine -tryptophan -histidine -adenine lacking SD medium (-LTHA-SD medium) plates. Colonies growing on the -LTHA-SD medium plates were picked and spread on -LTHA-SD medium plates containing X-a-Gal. Blue colonies were cultured for plasmid isolation, which was carried out using the YEASTMAKER TM Yeast Plasmid Isolation Kit (BD, Clontech) according to the manufacturer's instructions. Isolated plasmids were subcloned into competent E. coli cells. Transformants were spread out on Ampicillin containing plates for the selection of clones bearing the pGADT7-Rec library vector. Inserts of the pGADT7-Rec vector were characterized by sequence analysis.
To avoid false positive results, the candidate plasmid CHD8-pGADT7-Rec (amino acids 1789 -2091) was retransformed into AH109 yeast cells together with the empty bait vector pGBKT7 and selected on -LTHA-SD plates. No colonies were able to survive, indicating lack of self-activation of the system by the CHD8-pGADT7-Rec plasmid.
Direct yeast two hybrid. Direct yeast two-hybrid analysis was performed for confirmation of the CHD7 -CHD8 interaction. For this purpose, the identified CHD8-pGADT7-Rec prey plasmid and the CHD7-CR1-3-pGBKT7 bait plasmid were co-transformed into AH109 yeast strain cells. The co-transformants were grown on -LT-SD medium plates for transformation control and the interaction was verified on selective -LTHA-SD medium plates.
To specify the CHD7 -CHD8 interacting area, we generated three constructs CHD7-CR1-pGBKT7, CHD7-CR2-pGBKT7 and CHD7-CR3-pGBKT7 which divide the CHD7-CR1-3-pGBKT7 bait plasmids (amino acids 1591 -2181) in three different parts (Figs 1 and 2A) . The first fragment consists of the CR1 region and corresponds to amino acids 1593 -1768. The second fragment spans the CR2 part (amino acids 1701-1948), while the third fragment consists Human Molecular Genetics, 2010, Vol. 19, No. 14 2863 of the SANT domain and the CR3 region, corresponding to amino acids 1950 -2172. These CHD7 fragments were subcloned into the pGBKT7 vector (Clontech) and the three constructs CHD7-CR1-pGBKT7, CHD7-CR2-pGBKT7 and CHD7-CR3-pGBKT7 were used as baits for direct yeast twohybrid analysis.
To study the effect of known CHD7 missense mutations on the CHD7 -CHD8 interaction, the bait plasmids CHD7-His2096Arg-pGBKT7, CHD7-Val2102Ile-pGBKT7, CHD7-Gly2108Arg-pGBKT7 and CHD7-Trp2091Arg-pGBKT7 were generated by introducing one of the missense mutations (His2096Arg, Val2102Ile Gly2108Arg and Trp2091Arg) into the CHD7 region spanning amino acids 1950 -2172. An overview of the used plasmids is given in Figure 1 .
To narrow down the interacting area of CHD8, we created two prey constructs, CHD8-pGADT7-1 (amino acids 1789 -1983) and CHD8-pGADT7-2 (amino acids 1985-2091) dividing the CHD8 interacting area found in the initial library screen. All plasmids were checked for the correct sequence and reading frame by sequence analysis.
Cell culture
HeLa cells were cultured in Dulbecco's modified Eagle's media (DMEM) (PAN BIOTECH), supplemented with 10% foetal calf serum (PAN BIOTECH) and 1% penicillin/streptomycin (PAN BIOTECH). For transfection, cells were plated into two chamber culture slides (BD Falcon) and 50 ml flasks (Sarstedt). After 24 h when the cells' confluence reached about 70-80%, they were transfected with the plasmid DNA using OptiMEM serum-free medium (Gibco) and Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's instruction. After transfection, cells were grown for additional 24 h in DMEM.
Co-immunoprecipitation
For co-immunoprecipitation studies, we generated the plasmid CHD7-CR1-3-pCMV-HA by cloning a part of the CHD7 gene (amino acids 1593 -2178, NP_060250.2) in frame to the hemagglutinin (HA) epitope tag into the pCMV-HA vector (Clontech). A part of the CHD8 gene (amino acids 1789 -2302, NP_065971.2) was cloned in frame to the N-terminal c-Myc epitope tag into the pCMV-Myc vector (Clontech) for the construction of the CHD8-pCMV-c-Myc plasmid. The CHD7 missense mutations (His2096Arg, Val2102Ile Gly2108Arg and Trp2091Arg) were introduced into the CHD7-CR1-3-pCMV-HA plasmid, leading to the four new plasmids CHD7-His2096Arg-pCMV-HA, CHD7-Val2102Ile-pCMV-HA, CHD7-Gly2108Arg-pCMV-HA and CHD7-Trp2091Arg-pCMV-HA. The correct reading frame and sequence was confirmed by sequence analysis.
HeLa cells cultured in 50 ml flasks (Sarstedt) were transiently co-transfected with one of the CHD7 constructs (wildtype plasmid CHD7-CR1-3-pCMV-HA or mutant constructs) and CHD8-pCMV-c-Myc. After incubation for 24 h at 378C, transfected cells were washed twice with ice-cold DPBS. After washing, the cells were treated for 30 min on ice with 400 ml lysis buffer (Immunoprecipitation kit, Roche). Centrifugation at 14 000g for 20 min was carried out to remove cell debris. Forty microlitre of total protein extract was used for western blot analysis. When both transfected proteins were detected by western blot analysis, the remaining protein extract which was stored at 48C was incubated with either 1 mg of monoclonal anti-HA (Roche) or 1:100 diluted anti-c-Myc (Millipore) antibody at 48C overnight. Eighty microlitre of protein G (Immunoprecipitation kit, Roche) was added to the immunocomplex and incubated for 2 h at 48C. Centrifugation at 350 rpm for 3 min was carried out to collect the agarose beads. The beads were washed two times in 500 ml lysis buffer to remove unbound proteins. A resuspension of the beads in NuPAGE LDS Sample buffer (Invitrogen) with 0.1 M DTT followed. After denaturation for 10 min at 758C, the denaturated beats were loaded onto a 4 -12% NuPAGE Bis -Tris gel (Invitrogen). Proteins were immunoblotted with the anti-c-Myc antibody (Millipore) at a dilution of 1:500 or the anti-HA antibody (Roche) at a dilution of 1:1000. The following secondary antibodies were used: alkaline phosphatase labelled anti-mouse antibody produced in goat (SIGMA) was used for anti-c-Myc and horseradish peroxidase labelled anti-rat antibody produced in goat (Thermo Scientific) was used for anti-HA detection.
Bimolecular fluorescence complementation assay (BiFC-Assay)
For the BiFC-Assay, we cloned a part of the CHD7 gene (amino acids 1596-2178, NP_060250.2) in the FPCA-V1 vector and a part of the CHD8 gene (amino acids 1791-2302, NP_065971.2) in the FPCA-V2 vector. The FPCA-V1 vector was generated from the pEGFP-N1 vector (BD Bioscience). The FPCA-V1 vector contains a CMV promotor followed by a multiple cloning site in which we introduced the CHD7 part, a spacer region and the C-terminal end of EGFP (amino acids 158 -239). The FPCA-V2 vector, generated from the pQM-Ntag/B plasmid (Abcam, UK), contains a CMV promoter, followed by an E2 tag, the N-terminal part of EGFP (amino acids 1 -157), a spacer and the multiple cloning site in which we introduced the CHD8 part. HeLa cells were co-transfected with 0.5 mg of each construct. After incubation for 24 h at 378C, the cells were washed with DPBS, fixed with 4% paraformaldehyde and again washed with DPBS. After the washing step, cover slips were attached onto slides using Vectashield mounting solution containing DAPI (4,6-diamidino-2-phenylindole). Fluorescence imaging was performed using the Olympus BX60 microscope (Olympus, Hamburg, Germany).
Mutational analysis
CHD8 analysis was performed in 25 patients suspected of CHARGE syndrome, where the sequence and deletion analysis (MLPA, MRC Holland) of the CHD7 gene revealed no mutation. The coding sequence of all 37 coding exons and flanking intronic sequences of the CHD8 gene were analysed by PCR and sequenced in both directions in CHD7 negative CHARGE patients. Primer sequences and PCR conditions are available on request.
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